DiagnosTear Technologies, Inc. (DTR) Stock Price & Analysis

0 Followers

DTR Stock Chart & Stats

CA$0.25CA$0.00(0.00%)

At close: Nov 10 4:00 PM EST

Day’s Range: CAD 0.25 - CAD 0.25
52-Week Range: CAD 0.21 - CAD 0.88
Previous Close: CAD 0.25
Volume: N/A
Average Volume (3M): 2,100
Market Cap: CAD 15.16M
Enterprise Value: CAD 19.11M
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): CAD 0
Price to Earnings (P/E): ―
Beta: -0.48
Next Earnings: Nov 24, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

DiagnosTear Technologies, Inc. News

DiagnosTear Seeks FDA Guidance for TeaRx Red Eye Diagnostic Test

The latest update is out from DiagnosTear Technologies, Inc. ( ($TSE:DTR) ). DiagnosTear Technologies has filed a pre-submission request with the U.S. Food and Drug Administration for its TeaRx Red

2M agoDTR

DiagnosTear to Raise C$1.4 Million in Non-Brokered Private Placement

DiagnosTear Technologies, Inc. ( ($TSE:DTR) ) just unveiled an update. DiagnosTear Technologies Inc. plans to raise up to C$1.4 million through a non-brokered private placement of 2.8 million units priced

2M agoDTR

DiagnosTear Wins French Approvals to Launch TeaRx Red Eye Clinical Study with AlyaTec

An announcement from DiagnosTear Technologies, Inc. ( ($TSE:DTR) ) is now available. DiagnosTear Technologies has secured all necessary regulatory and ethics approvals in France to begin a clinical study of

8M agoDTR

DiagnosTear Partners with Hanson Medical to Advance TeaRx Dry-Eye Test in U.K. Market

DiagnosTear Technologies, Inc. ( ($TSE:DTR) ) just unveiled an update. DiagnosTear Technologies has signed a Letter of Intent with U.K.-based Hanson Medical to exclusively explore a commercial partnership for the

8M agoDTR

DiagnosTear Targets Indian Ophthalmic Market With TeaRx Distribution LOI

The latest announcement is out from DiagnosTear Technologies, Inc. ( ($TSE:DTR) ). DiagnosTear Technologies has signed a Letter of Intent with Hyderabad-based Renovate Biologicals to support the commercial evaluation and

9M agoDTR

DiagnosTear Reports Strong Interim Data for TeaRx Red Eye Diagnostic Platform

An announcement from DiagnosTear Technologies, Inc. ( ($TSE:DTR) ) is now available. DiagnosTear Technologies reported highly encouraging interim clinical results from its ongoing multi-center study in Israel evaluating its TeaRx

9M agoDTR

DiagnosTear Technologies Confirms No Material Change Amid Market Activity

DiagnosTear Technologies, Inc. ( ($TSE:DTR) ) has shared an update. DiagnosTear Technologies Inc. announced that there is no material change in its operations despite a recent increase in market activity,

11M agoDTR

DiagnosTear Partners with AlyaTec for TeaRx™ Red Eye Clinical Study

DiagnosTear Technologies, Inc. ( ($TSE:DTR) ) has provided an announcement. DiagnosTear Technologies Inc. has announced a collaboration with AlyaTec to conduct a clinical study aimed at advancing the analytical validation

11M agoDTR

DiagnosTear Partners with LV Prasad Eye Institute for Red Eye Diagnostic Advancement

An update from DiagnosTear Technologies, Inc. ( ($TSE:DTR) ) is now available. DiagnosTear Technologies Inc. has announced a collaboration with LV Prasad Eye Institute to advance the clinical validation of

11M agoDTR

DiagnosTear Technologies Secures $925,000 in Private Placement

DiagnosTear Technologies, Inc. ( ($TSE:DTR) ) has shared an update. DiagnosTear Technologies Inc. announced the successful closing of a non-brokered private placement of units, raising CDN $925,000. The funds will

11M agoDTR

DTR FAQ

What was DiagnosTear Technologies, Inc.’s price range in the past 12 months?

DiagnosTear Technologies, Inc. lowest stock price was C$0.21 and its highest was C$0.88 in the past 12 months.

What is DiagnosTear Technologies, Inc.’s market cap?

DiagnosTear Technologies, Inc.’s market cap is C$15.16M.

When is DiagnosTear Technologies, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were DiagnosTear Technologies, Inc.’s earnings last quarter?

DiagnosTear Technologies, Inc. released its earnings results on Aug 28, 2026. The company reported -C$0.021 earnings per share for the quarter.

Is DiagnosTear Technologies, Inc. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does DiagnosTear Technologies, Inc. pay dividends?

DiagnosTear Technologies, Inc. does not currently pay dividends.

What is DiagnosTear Technologies, Inc.’s EPS estimate?

DiagnosTear Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does DiagnosTear Technologies, Inc. have?

DiagnosTear Technologies, Inc. has 60,638,336 shares outstanding.

What happened to DiagnosTear Technologies, Inc.’s price movement after its last earnings report?

DiagnosTear Technologies, Inc. reported an EPS of -C$0.021 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of DiagnosTear Technologies, Inc.?

Currently, no hedge funds are holding shares in TSE:DTR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description